Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 1
2018 1
2019 4
2020 5
2021 3
2023 1
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non-Small Cell Lung Cancer.
Tsukita Y, Tozuka T, Kushiro K, Hosokawa S, Sumi T, Uematsu M, Honjo O, Yamaguchi O, Asao T, Sugisaka J, Saito G, Shiihara J, Morita R, Katakura S, Yasuda T, Hisakane K, Miyauchi E, Morita S, Kobayashi K, Asahina H. Tsukita Y, et al. Among authors: sugisaka j. JAMA Oncol. 2024 Apr 1;10(4):439-447. doi: 10.1001/jamaoncol.2023.6277. JAMA Oncol. 2024. PMID: 38451530
Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer.
Shibaki R, Fujimoto D, Nozawa T, Sano A, Kitamura Y, Fukuoka J, Sato Y, Kijima T, Matsumoto H, Yokoyama T, Miura S, Hata A, Tamiya M, Taniguchi Y, Sugisaka J, Furuya N, Tanaka H, Yamamoto N, Koh Y, Akamatsu H. Shibaki R, et al. Among authors: sugisaka j. J Immunother Cancer. 2024 Feb 15;12(2):e007987. doi: 10.1136/jitc-2023-007987. J Immunother Cancer. 2024. PMID: 38360040 Free PMC article.
Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101).
Tsuji K, Mizugaki H, Yokoo K, Kobayashi M, Kawashima Y, Kimura N, Yokouchi H, Kikuchi H, Sumi T, Kawai Y, Kobashi K, Morita R, Ito K, Kitamura Y, Minemura H, Nakamura K, Aso M, Honjo O, Tanaka H, Takashina T, Tsurumi K, Sugisaka J, Tsukita Y, Konno S, Oizumi S. Tsuji K, et al. Among authors: sugisaka j. Cancer Sci. 2024 Apr;115(4):1273-1282. doi: 10.1111/cas.16094. Epub 2024 Jan 29. Cancer Sci. 2024. PMID: 38287788 Free PMC article.
Gene expression signatures as candidate biomarkers of response to PD-1 blockade in non-small cell lung cancers.
Aiba T, Hattori C, Sugisaka J, Shimizu H, Ono H, Domeki Y, Saito R, Kawana S, Kawashima Y, Terayama K, Toi Y, Nakamura A, Yamanda S, Kimura Y, Suzuki Y, Niida A, Sugawara S. Aiba T, et al. Among authors: sugisaka j. PLoS One. 2021 Nov 29;16(11):e0260500. doi: 10.1371/journal.pone.0260500. eCollection 2021. PLoS One. 2021. PMID: 34843570 Free PMC article.
Association of immune-related pneumonitis with clinical benefit of anti-programmed cell death-1 monotherapy in advanced non-small cell lung cancer.
Ono K, Ono H, Toi Y, Sugisaka J, Aso M, Saito R, Kawana S, Aiba T, Odaka T, Matsuda S, Saito S, Narumi A, Ogasawara T, Shimizu H, Domeki Y, Terayama K, Kawashima Y, Nakamura A, Yamanda S, Kimura Y, Honda Y, Sugawara S. Ono K, et al. Among authors: sugisaka j. Cancer Med. 2021 Jul;10(14):4796-4804. doi: 10.1002/cam4.4045. Epub 2021 Jun 13. Cancer Med. 2021. PMID: 34121358 Free PMC article.
Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Toi Y, Sugawara S, Sugisaka J, Ono H, Kawashima Y, Aiba T, Kawana S, Saito R, Aso M, Tsurumi K, Suzuki K, Shimizu H, Domeki Y, Terayama K, Nakamura A, Yamanda S, Kimura Y, Honda Y. Toi Y, et al. Among authors: sugisaka j. JAMA Oncol. 2019 Mar 1;5(3):376-383. doi: 10.1001/jamaoncol.2018.5860. JAMA Oncol. 2019. PMID: 30589930 Free PMC article.
Successful application of lorlatinib in a 23-year-old patient with anaplastic lymphoma kinase (ALK)-positive lung cancer and multiple brain metastases.
Murakami Y, Kawashima Y, Chiba S, Hara S, Yamazaki Y, Doman T, Saito S, Odaka T, Ogasawara T, Shimizu H, Sugisaka J, Aiba T, Toi Y, Yamanda S, Kimura Y, Sugawara S. Murakami Y, et al. Among authors: sugisaka j. Cancer Rep (Hoboken). 2024 Feb;7(2):e1981. doi: 10.1002/cnr2.1981. Epub 2024 Jan 11. Cancer Rep (Hoboken). 2024. PMID: 38212894 Free PMC article.
Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab.
Sugisaka J, Toi Y, Taguri M, Kawashima Y, Aiba T, Kawana S, Saito R, Aso M, Tsurumi K, Suzuki K, Shimizu H, Ono H, Domeki Y, Terayama K, Nakamura A, Yamanda S, Kimura Y, Honda Y, Sugawara S. Sugisaka J, et al. JMA J. 2020 Jan 15;3(1):58-66. doi: 10.31662/jmaj.2019-0005. Epub 2019 Nov 8. JMA J. 2020. PMID: 33324776 Free PMC article.
17 results